• Huabin Yin, Xinghai Yang, Wei Xu, Binbin Li, Bo Li, Ting Wang, Tong Meng, Peng Wang, Tielong Liu, Wang Zhou, and Jianru Xiao.
• Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.
• Eur Spine J. 2015 Aug 1;24(8):1747-53.

PurposeAggressive giant cell tumor (GCT) is an important subtype of GCT and is relatively rare in the spine. There is little published information regarding this subject. The objective of our study is to discuss prognostic factors for primary aggressive GCT in the spine.MethodsA retrospective study of patients who had primary aggressive GCT in the spine and underwent surgical treatment at our center between 2000 and 2012 was conducted. Univariate and multivariate analyses were performed to identify the factors that might affect recurrence. T test, Chi-square test and rank sum test were used to analyze a single factor for recurrence, and factors with P ≤ 0.1 were subjected to multivariate analyses by binary logistic regression analyses. P values of ≤0.05 were considered statistically significant.ResultsA total of 71 patients with primary aggressive GCT in the spine were included in the study. The mean follow-up period was 73.9 (range 23-167) months. Recurrence was detected in 24 patients after the initial surgery in our center with a recurrence rate of 33.8 %. The statistical analyses suggested that age more than 40 years, pathology grade III, total en bloc spondylectomy, and bisphosphonate treatment were independent prognostic factors for recurrence of primary aggressive GCT in the spine.ConclusionTotal en bloc spondylectomy together with bisphosphonate treatment could significantly decrease recurrence risk of primary aggressive GCT in the spine. Jaffe grade III was an adverse prognostic factor for recurrence, while age less than 40 years was a favorable prognostic factor.

39 keywords...

hide…